BIXT · XBRL financial data
Bioxytran financial statements, every fiscal year
The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BIXT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 545 | 2,014 | 978 | 1,149 | 112 | 454 |
| General and administrative | 476 | 1,618 | 934 | 1,403 | 1,168 | 648 |
| Total operating expenses | 1,269 | 4,214 | 2,134 | 3,800 | 2,223 | 1,843 |
| Operating income (loss) | (1,269) | (4,214) | (2,134) | (3,800) | (2,223) | (1,843) |
| Interest expense | 1,015 | 237 | — | 193 | 84 | 134 |
| Net income (loss) | (2,543) | (4,528) | (2,464) | (4,473) | (2,367) | (2,123) |
| Earnings per share, basic USD per share | — | (0.04) | (0.02) | (0.03) | (0.02) | (0.02) |
| Earnings per share, diluted USD per share | — | — | (0.02) | (0.03) | (0.02) | (0.02) |
| Weighted average shares, basic thousands of shares | — | 106,252 | 115,139 | 133,973 | 138,599 | 91,843 |
| Weighted average shares, diluted thousands of shares | — | — | 112,712 | 133,973 | 138,599 | 91,843 |
Balance sheet
CSVFiscal years (BIXT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 42 | 72 | 295 | 26 | 5 | 510 |
| Total current assets | 316 | 72 | 295 | 26 | 5 | 513 |
| Total assets | 326 | 119 | 371 | 139 | 139 | 659 |
| Accounts payable | — | — | 710 | — | — | — |
| Total current liabilities | 2,268 | 3,277 | 3,663 | 3,244 | 1,931 | 3,250 |
| Total deposits | — | — | — | — | — | 112 |
| Total liabilities | 2,268 | 3,277 | 3,663 | 3,244 | 1,931 | 3,250 |
| Accumulated deficit | (4,722) | (8,754) | (11,218) | (15,699) | (18,921) | (21,044) |
| Total stockholders' equity | (1,941) | (3,158) | — | — | (1,792) | (2,591) |
| Total liabilities and equity | 326 | 119 | 371 | 139 | 139 | 659 |
| Common shares outstanding (cover page) thousands of shares | 100,750 | 110,841 | 123,502 | 166,493 | 88,882 | 113,362 |
Cash flows
CSVFiscal years (BIXT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (2,543) | (4,528) | (2,464) | (4,473) | (2,367) | (2,123) |
| Stock-based compensation | 248 | 583 | 178 | 88 | — | — |
| Net cash from operating activities | (1,099) | (1,697) | (1,806) | (775) | (56) | (526) |
| Net cash from investing activities | (10) | (37) | (32) | (44) | (28) | (23) |
| Proceeds from issuing common stock | 600 | 950 | — | — | 63 | 439 |
| Proceeds from issuing equity | — | — | — | 550 | 63 | — |
| Net cash from financing activities | 981 | 1,765 | 2,061 | 550 | 63 | 1,054 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Bioxytran | 177 | not reported | (350)* | 114.7M | 0.5 quarters | 10-QJun 30, 2026 |
| Artelo Biosciences | 4,198 | not reported | (5,033)* | 4.6M | 0.8 quarters | 10-QJun 30, 2026 |
| Raphael Pharmaceutical | 1 | not reported | 0* | 20.2M | — | 10-QJun 30, 2026 |
| Oncotelic Therapeutics | 186 | 250 | (92)* | 457.5M | 2.0 quarters | 10-QJun 30, 2026 |
| Alaunos Therapeutics | 124 | 0 | (300)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| TherapeuticsMD | 9,189 | not reported | not reported | 11.6M | — | 10-QJun 30, 2026 |
| BioCardia | 4,117 | not reported | (1,735)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
| Traws Pharma | 5,016 | not reported | (7,504)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| Mannatech | 6,034 | 26,650 | (792)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.